Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Current Liabilities (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Total Current Liabilities for 9 consecutive years, with $81.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 15.46% year-over-year to $81.3 million, compared with a TTM value of $81.3 million through Dec 2025, down 15.46%, and an annual FY2025 reading of $81.3 million, down 15.46% over the prior year.
  • Total Current Liabilities was $81.3 million for Q4 2025 at Puma Biotechnology, down from $82.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $140.4 million in Q1 2021 and bottomed at $48.2 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $89.4 million, with a median of $84.7 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities plummeted 58.79% in 2022, then soared 103.77% in 2024.
  • Year by year, Total Current Liabilities stood at $109.6 million in 2021, then dropped by 29.29% to $77.5 million in 2022, then increased by 28.26% to $99.4 million in 2023, then decreased by 3.29% to $96.1 million in 2024, then fell by 15.46% to $81.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for PBYI at $81.3 million in Q4 2025, $82.7 million in Q3 2025, and $79.1 million in Q2 2025.